Pfizer's Xeljanz picks up a third indication in the US - PMLiVE
Molecules | Free Full-Text | Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates
After delays, Pfizer's blockbuster-to-be eczema drug Cibinqo snags FDA nod | Fierce Pharma
How JAK Inhibitor Hair Loss Treatments Were Discovered
The EU CHMP recommends approval of Pfizer's 2 JAK inhibitors Cibinqo (abxitinib) and Xeljanz (tofacitinib)! - Knowledge - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd
JAK inhibitor edge for Incyte and Eli Lilly over Pfizer for Covid-19
Frontiers | Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
JAK Inhibitors Are Coming and They Are the Biggest Eczema Development in Years | National Eczema Association
JAK Inhibitor Misses Endpoint in Safety Study. Now What? | MedPage Today
Pfizer Announces FDA Approval of XELJANZ® XR (tofacitinib citrate) Extended-Release Tablets, the First and Only Once-Daily Oral JAK Inhibitor Treatment for Rheumatoid Arthritis | Business Wire
Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis | Nature Biotechnology
Another JAK Inhibitor Shows Mortality Benefit in COVID-19 | MedPage Today
Ritlecitinib (PF-06651600) | ≥99%(HPLC) | Selleck | JAK inhibitor
Pfizer Strikes JAK Inhibitor Deal Worth Up to $250 Million With Theravance | BioSpace
Latest Pharma News and Updates - Pfizer, Lilly, Innovent, Bayer, and GSK
US, Europe review safety of JAK inhibitors. What about Korea? < Policy < Article - KBR
Janus kinase 3 inhibitor - Wikipedia
Trial Data Confirm Heightened Risks With JAK Inhibitor | MedPage Today
FDA approves JAK inhibitors as 2nd-line systemic therapy in atopic dermatitis < Pharma < Article - KBR
Selective Janus kinase inhibitors come of age | Nature Reviews Rheumatology
Janus Kinase Inhibitors Offer New Treatment for Rheumatoid Arthritis, Psoriatic Arthritis, Colitis
JAK inhibitors from Pfizer, AbbVie and Lilly hit with dreaded FDA heart safety, cancer warnings | Fierce Pharma
